Faricimab Rapidly Reduces Retinal Fluid in nAMD in TENAYA and LUCERNE
Chui Ming Gemmy Cheung, MBBS | Image Credit: Duke NUS Medical School A recent post hoc analysis identified faricimab as exhibiting greater improvements in anatomic outcomes than aflibercept during the head-to-head testing phase of the TENAYA and LUCERNE trials in neovascular age-related macular degeneration (nAMD). TENAYA and LUCERNE were randomized, double-masked, non-inferiority trials across 271 … Read more